| Literature DB >> 28912717 |
Wenjuan Xu1, Ziyi Wei2, Jiaojiao Dong2, Feipeng Duan2, Kuikui Chen2, Chang Chen1, Jie Liu2, Xiaowei Yang1, Lianming Chen2, Hongbin Xiao2, An Liu1.
Abstract
Atherosclerosis (AS) is a chronic disorder of large arteries that is a major risk factors of high morbidity and mortality. Oxidative modification LDL is one of the important contributors to atherogenesis. Macrophages take up ox-LDL and convert into foam cells, which is the hallmark of AS. To advance the understanding of the metabolic perturbation involved in ox-LDL induced macrophage-derived foam cells and discover the potential biomarkers of early AS, a global metabolomics approach was applied based on UHPLC-QTOF/MS. Multivariate statistical analyses identified five metabolites (25-azacholesterol, anandamide, glycocholate, oleoyl ethanolamide, and 3-oxo-4, 6-choladienoate) for distinguishing foamy macrophages from controls. Among the six main metabolic pathways, the unsaturated fatty acid, especially arachidonic acid metabolism, contributed importantly to early AS. A new biomarker, anandamide (AEA), whose synthesis and metabolism in macrophages are disturbed by overloaded ox-LDL, results in metabolic obstruction. This study is the first to investigate the metabolic disturbance in macrophage-derived foam cells induced by ox-LDL and screen potential biomarkers and metabolic pathways associated with early AS. Our findings provide a new insight in the underlying pathophysiological mechanisms and also help to identify novel targets for the intervention of AS.Entities:
Keywords: anandamide over-accumulation; atherosclerosis; macrophage-derived foam cells; metabolomics; oxidized-LDL
Year: 2017 PMID: 28912717 PMCID: PMC5583968 DOI: 10.3389/fphar.2017.00586
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
List of candidate biomarkers screened by statistical analysis (p < 0.05, fold change >2.0).
| Compounds | KEGG | HMDB | Lipid maps | Regulation |
|---|---|---|---|---|
| 5,6-DHET | C14772 | LMFA03050004 | Up | |
| 25-Azacholesterol | HMDB01028 | LMST01010212 | Up | |
| 3-Oxo-4,6-Choladienoate | HMDB00476 | LMST04010235 | Up | |
| 5α-Androstane-3,17-dione | C00674 | LMST02020085 | Up | |
| 9- | C15493 | LMPR01090022 | Up | |
| 9,12,13-TriHOME | C14833 | HMDB04708 | LMFA02000014 | Up |
| 9Z-Octadecenedioic acid | C19618 | LMFA01170055 | Up | |
| Anandamide | C11695 | LMFA08040001 | Up | |
| γ-Nonalactone | C08501 | Up | ||
| Glycocholate | C01921 | LMST05030001 | Up | |
| LysoPE [18:1(11Z)/0:0] | HMDB11505 | Down | ||
| C13914 | HMDB13645 | LMSP01070001 | Up | |
| Oleoyl ethanolamide | HMDB02088 | LMFA08040015 | Up | |
| Pregnenolone | C01953 | HMDB00253 | LMST02030088 | Up |
| 5-Oxoproline | C01879 | HMDB00267 | Up |
List of candidate biomarkers screened by OPLS-DA (VIP value > 1.0).
| Compounds | KEGG | HMDB | Lipid maps | Regulation |
|---|---|---|---|---|
| 25-Azacholesterol | HMDB01028 | LMST01010212 | Up | |
| 3-Oxo-4,6-Choladienoate | HMDB00476 | LMST04010235 | Up | |
| 6β,7β-Dihydroxykaurenoic acid | C11876 | Up | ||
| Amphotericin B | C06573 | HMDB14819 | LMPK06000002 | Up |
| Anandamide | C11695 | HMDB04080 | LMFA08040001 | Up |
| Glycocholate | C01921 | HMDB00138 | LMST05030001 | Up |
| LysoPE [18:1(11Z)/0:0] | HMDB11505 | Down | ||
| MG (20:0/0:0/0:0) | HMDB11572 | Up | ||
| C13914 | HMDB13645 | LMSP01070001 | Up | |
| Oleoyl ethanolamide | HMDB02088 | LMFA08040015 | Up | |
| Pentosidine | HMDB03933 | Up | ||
| PG [18:3(9Z,12Z,15Z)/18:1(9Z)] | HMDB10679 | Up | ||
| Pregnenolone | C01953 | HMDB00253 | LMST02030088 | Up |
| 5-Oxoproline | C01879 | HMDB00267 | Up |